Rite Aid has been executing a multi-year turnaround initiative focused on improving operational efficiency and leveraging its pharmacy expertise. The company maintains a significant presence in the mid-market pharmacy space and continues pursuing strategic initiatives to enhance profitability. However, the company faces ongoing challenges in maintaining margins amid competitive pressures in retail pharmacy.
Cyborg Score Rationale
Rite Aid operates a significant business with stable revenue, but faces persistent profitability challenges and ongoing restructuring needs. The company has demonstrated losses in recent periods and carries the complexity of managing both retail and PBM operations during a transitional period.
Top Insights
Large trailing revenue base of ~$23.5B as of April 2026, though revenue has declined modestly from prior years
Company continues multi-year strategic initiatives including store closures and facility exits to improve performance
Operates integrated Retail Pharmacy and Pharmacy Services segments; PBM operations are core to growth strategy
Facing persistent margin pressures and restructuring charges as part of ongoing transformation efforts
Named Competitors
Walgreens Boots Alliance — National pharmacy chain and healthcare company
CVS Health — Integrated pharmacy and health services provider
Express Scripts — PBM and healthcare management services
Caremark — Pharmacy benefits management services
Recent Developments
(April 2026) TTM revenue at $23.47 billion according to latest financial reports
(Q1 2023) Reported net loss of $306.7 million despite progress on turnaround initiatives and strong prescription growth
(2022) Revenue of $24.06 billion representing a slight decrease from prior year
Open the full interactive Rite Aid Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.